Scarica l'app Stockscreener
4.36
3.32%
0.14
Dopo l'orario di chiusura:
4.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.22
Aprire:
$4.2
Volume 24 ore:
2.06M
Relative Volume:
4.11
Capitalizzazione di mercato:
$260.46M
Reddito:
-
Utile/perdita netta:
$-40.33M
Rapporto P/E:
-0.7303
EPS:
-5.97
Flusso di cassa netto:
$-39.53M
1 W Prestazione:
-0.46%
1M Prestazione:
+13.25%
6M Prestazione:
+65.78%
1 anno Prestazione:
+196.60%
Intervallo 1D:
$3.95
$4.42
Intervallo di 1 settimana:
$3.95
$4.76
Portata 52W:
$1.43
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Confronta ELDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
4.36 | 260.46M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Eledon Pharmaceuticals adjusts CEO bonus structure - Investing.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Has Negative Outlook for ELDN Q4 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for ELDN Earnings - MarketBeat
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress - Investing.com Australia
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright - MarketBeat
FY2024 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - MarketBeat
Lifesci Capital Issues Optimistic Outlook for ELDN Earnings - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance
Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St
Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian
Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
Amyotrophic Lateral Sclerosis Treatment Market to hit USD 1.1 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):